Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 1
1993 1
1996 2
1997 4
1998 6
1999 5
2000 5
2001 8
2002 5
2003 2
2004 4
2005 2
2006 5
2007 2
2008 3
2009 2
2010 3
2011 2
2012 4
2013 3
2014 3
2015 2
2016 2
2017 2
2018 4
2019 2
2020 2
2021 4
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
An oral antisense oligonucleotide for PCSK9 inhibition.
Gennemark P, Walter K, Clemmensen N, Rekić D, Nilsson CAM, Knöchel J, Hölttä M, Wernevik L, Rosengren B, Kakol-Palm D, Wang Y, Yu RZ, Geary RS, Riney SJ, Monia BP, Isaksson R, Jansson-Löfmark R, Rocha CSJ, Lindén D, Hurt-Camejo E, Crooke R, Tillman L, Rydén-Bergsten T, Carlsson B, Andersson U, Elebring M, Tivesten A, Davies N. Gennemark P, et al. Among authors: hurt camejo e. Sci Transl Med. 2021 May 12;13(593):eabe9117. doi: 10.1126/scitranslmed.abe9117. Sci Transl Med. 2021. PMID: 33980578
Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease.
Suur BE, Chemaly M, Lindquist Liljeqvist M, Djordjevic D, Stenemo M, Bergman O, Karlöf E, Lengquist M, Odeberg J, Hurt-Camejo E, Eriksson P, Ketelhuth DFJ, Roy J, Hedin U, Nyberg M, Matic L. Suur BE, et al. Among authors: hurt camejo e. Front Pharmacol. 2022 Sep 15;13:988561. doi: 10.3389/fphar.2022.988561. eCollection 2022. Front Pharmacol. 2022. PMID: 36188622 Free PMC article.
Phospholipase A(2) in vascular disease.
Hurt-Camejo E, Camejo G, Peilot H, Oörni K, Kovanen P. Hurt-Camejo E, et al. Circ Res. 2001 Aug 17;89(4):298-304. doi: 10.1161/hh1601.095598. Circ Res. 2001. PMID: 11509445 Review.
Phospholipase A2 enzymes and the risk of atherosclerosis.
Rosenson RS, Hurt-Camejo E. Rosenson RS, et al. Among authors: hurt camejo e. Eur Heart J. 2012 Dec;33(23):2899-909. doi: 10.1093/eurheartj/ehs148. Epub 2012 Jul 15. Eur Heart J. 2012. PMID: 22802388 Review.
Design of Selective sPLA2-X Inhibitor (-)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl]pyridine-2-yl}propanoic Acid.
Giordanetto F, Knerr L, Nordberg P, Pettersen D, Selmi N, Beisel HG, de la Motte H, Månsson Å, Dahlström M, Broddefalk J, Saarinen G, Klingegård F, Hurt-Camejo E, Rosengren B, Wikström J, Wågberg M, Brengdahl J, Rohman M, Sandmark J, Åkerud T, Roth RG, Jansen F, Ahlqvist M. Giordanetto F, et al. Among authors: hurt camejo e. ACS Med Chem Lett. 2018 Jun 23;9(7):600-605. doi: 10.1021/acsmedchemlett.7b00507. eCollection 2018 Jul 12. ACS Med Chem Lett. 2018. PMID: 30034586 Free PMC article.
Rupture of the atherosclerotic plaque: does a good animal model exist?
Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella A, von Eckardstein A, Exley A, Goddard M, Hofker M, Hurt-Camejo E, Kanters E, Kovanen P, Lorkowski S, McPheat W, Pentikäinen M, Rauterberg J, Ritchie A, Staels B, Weitkamp B, de Winther M; MAFAPS Consortium. Cullen P, et al. Among authors: hurt camejo e. Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):535-42. doi: 10.1161/01.ATV.0000060200.73623.F8. Epub 2003 Feb 6. Arterioscler Thromb Vasc Biol. 2003. PMID: 12615660 Free article. Review.
88 results